— Successful Clinical Development Would Enable Company’s Microbiome-Protecting Therapeutics to Cover all Three Beta-Lactam Antibiotic Classes — — Webcast Details Below for Microbiome Analyst & Investor Meeting Live Today at 9:00 a.m. EDT — ROCKVILLE, Md., June 3, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), this week presented initial data that support the […]
— GI Clinician and Scientist Most Recently Served in Leadership Positions at Quintiles and the U.S. Food & Drug Administration (FDA) — ROCKVILLE, Md., June 2, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced Klaus Gottlieb, MD, FACG, has
— Leading Clinicians to Discuss Novel Approaches to Treating IBS-C and Preventing C. difficile — — Webcast Scheduled at 9:00 a.m. EDT on Wednesday, June 3, 2015 — ROCKVILLE, Md., June 1, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific
Synthetic Biologics to Host Microbiome Analyst & Investor Meeting Read More »
— Company’s Program for Prevention of C. difficile Infection in Phase 2a Clinical Trial and on Target for Phase 2b Clinical Trial Initiation in 2H 2015 — ROCKVILLE, Md., May 19, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome while targeting pathogen-specific diseases,
— Company’s Irritable Bowel Syndrome with Constipation (IBS-C) Program to Reduce the Impact of Methane Gas in the Gut on Target to Initiate Phase 2 Clinical Trial in 2Q 2015 — ROCKVILLE, Md., May 18, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical-stage company focused on developing therapeutics to protect the microbiome
— Initiated Phase 2 for Prevention of C. difficile, Expected to Initiate Phase 2 for IBS-C by end of June 2015, and Expanded Leadership Team as Company Moves into Next Development Stage — — Conference Call Today, May 11, 2015, at 4:30 p.m. EDT — ROCKVILLE, Md., May 11, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE
— Appointment Reflects Company’s Expanded Clinical and Market Driven Focus — ROCKVILLE, Md., May 7, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a microbiome-focused, clinical-stage company developing therapeutics to protect the microbiome while targeting pathogen-specific diseases, announced Maureen Early joined the team in the newly created position of Vice President, Commercial. In her
Maureen Early Named Vice President, Commercial of Synthetic Biologics Read More »
— Executive Brings Significant Biotech Industry Leadership Experience to Team as Company Enters Next Phase of Development — ROCKVILLE, Md., May 4, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapeutics focused on protecting the microbiome, as well as treating other diseases, announced Steven A. Shallcross has been appointed Chief Financial
Steven Shallcross Named Chief Financial Officer of Synthetic Biologics Read More »
— Results Provide Support for Advancing SYN-005 into Clinic — ROCKVILLE, Md., April 27, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, announced that preclinical data from its novel SYN-005 program for the treatment of Pertussis were presented
— Data Supporting Development of Expanded C. difficile Preventive Therapeutics also Accepted for Presentation — ROCKVILLE, Md., April 1, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced that clinical data supporting the development of SYN-004,
